SCHEMBL25206285

SCHEMBL25206285

Cn1c(-c2cccnc2)nc2cccc(N)c2c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B2 P19099 3/20 0.47
▸ CYP11B1 P15538 1/20 0.47
▸ ELANE P08246 1/20 0.46
▸ MAPT P10636 4/20 0.44
▸ G6PD P11413 2/20 0.43
▸ TNF P01375 1/20 0.43
▸ IL1B P01584 1/20 0.43
▸ DDB1 Q16531 1/20 0.43
▸ CRBN Q96SW2 1/20 0.43
▸ IKZF3 Q9UKT9 1/20 0.43
▸ DYRK1A Q13627 1/20 0.42
▸ CYP2A6 P11509 1/20 0.41
▸ MDM2 Q00987 1/20 0.41
▸ DPP4 P27487 1/20 0.41
▸ DPP8 Q6V1X1 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ BACE1 P56817 1/20 0.41
▸ USP2 O75604 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ NCOA1 Q15788 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29364970 1.00 CYP11B2 (0.47) CYP11B2CYP11B1ELANEMAPTG6PD
SCHEMBL30426682 0.85 CYP11B2 (0.47) CYP11B2CYP11B1ELANEMAPTG6PD
SCHEMBL25230765 0.85 CYP11B2 (0.47) CYP11B2CYP11B1ELANEMAPTG6PD
SCHEMBL29052562 0.81 CYP11B2 (0.45) CYP11B2CYP11B1ELANEMAPTG6PD
SCHEMBL25206359 0.80 MAPT (0.47) CYP11B2CYP11B1ELANEMAPTG6PD
SCHEMBL25358905 0.79 CYP11B2 (0.49) CYP11B2CYP11B1ELANEMAPTG6PD
SCHEMBL29367068 0.74 NAMPT (0.41) CYP11B2CYP11B1ELANEMAPTG6PD
SCHEMBL26238112 0.74 NAMPT (0.41) CYP11B2CYP11B1ELANEMAPTG6PD
SCHEMBL25210159 0.72 ESR1 (0.45) MAPTCYP2A6HTT
SCHEMBL30427035 0.72 ESR1 (0.45) MAPTCYP2A6HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230286923-A1 QUINAZOLINONE HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-09-14 — — US disclosed
US-20230286923-A1 QUINAZOLINONE HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-09-14 — — US disclosed
US-20230286923-A1 QUINAZOLINONE HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2023-09-14 — — US disclosed
EP-4185380-A1 QUINAZOLINONE HSD17B13 INHIBITORS AND USES THEREOF Inipharm, Inc. (US) 2023-05-31 — — EP disclosed
CN-116194440-A Quinazolinone HSD17B13 inhibitors and uses thereof 伊尼制药公司 2023-05-30 — — CN disclosed
WO-2022020730-A1 QUINAZOLINONE HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. (US) 2022-01-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230286923-A1 QUINAZOLINONE HSD17B13 INHIBITORS AND USES THEREOF HSD17B3, HSD17B1, HSD17B13 CYP11B2 20/4885CYP11B1 12/4885ELANE 2585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback